Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression